Genetic heterogeneity in uveal melanoma assessed by multiplex ligation-dependent probe amplification
- PMID: 20484589
- DOI: 10.1167/iovs.09-5004
Genetic heterogeneity in uveal melanoma assessed by multiplex ligation-dependent probe amplification
Abstract
Purpose: To determine intratumor genetic heterogeneity in uveal melanoma (UM) by multiplex ligation-dependent probe amplification (MLPA) in formalin-fixed, paraffin-embedded (FFPE) tumor tissues.
Methods: DNA was extracted from whole tumor sections and from two to nine different areas microdissected from 32 FFPE UMs. Thirty-one loci on chromosomes 1, 3, 6, and 8 were tested with MLPA for copy number changes. The tumor was considered heterogeneous at a locus if (1) the difference in dosage quotients (DQs) of any two areas was 0.2 or more, and (2) the DQs of the areas belonged to different ranges.
Results: Comparison of MLPA data obtained from microdissected areas of the UMs showed heterogeneity in 1 to 26 examined loci in 24 (75%) tumors, with only 25% of the tumors being homogeneous. Intratumor heterogeneity of 3p12.2, 6p21.2, and 8q11.23 was most common, occurring in >30% of the UMs. Gains of chromosome 3 were observed in four UMs, with three of these tumors showing the highest degree of heterogeneity. Copy number variation was associated with differences in tumor cell type, but not with differences in tumor pigmentation or reactive inflammation. UMs with genetic heterogeneity across multiple sample sites showed equivocal MLPA results when the whole tumor section was examined. These results suggest that different clones dilute MLPA results.
Conclusions: Heterogeneity of chromosomal abnormalities of chromosomes 1, 3, 6, and 8 is present in most UMs. This heterogeneity causes equivocal MLPA results. One random tumor sample may not be representative of the whole tumor and, therefore, may be insufficient for prognostic testing.
Similar articles
-
Comparison of formalin-fixed and snap-frozen samples analyzed by multiplex ligation-dependent probe amplification for prognostic testing in uveal melanoma.Invest Ophthalmol Vis Sci. 2012 May 4;53(6):2647-52. doi: 10.1167/iovs.12-9584. Invest Ophthalmol Vis Sci. 2012. PMID: 22427594
-
Multiplex ligation-dependent probe amplification analysis of uveal melanoma with extraocular extension demonstrates heterogeneity of gross chromosomal abnormalities.Invest Ophthalmol Vis Sci. 2011 Jul 29;52(8):5559-64. doi: 10.1167/iovs.10-6845. Invest Ophthalmol Vis Sci. 2011. PMID: 21659309
-
Whole-genome microarray detects deletions and loss of heterozygosity of chromosome 3 occurring exclusively in metastasizing uveal melanoma.Invest Ophthalmol Vis Sci. 2010 Oct;51(10):4884-91. doi: 10.1167/iovs.09-5083. Epub 2010 May 5. Invest Ophthalmol Vis Sci. 2010. PMID: 20445121
-
[Genomic techniques used in uveal melanoma: a literature review].J Fr Ophtalmol. 2011 Apr;34(4):259-64. doi: 10.1016/j.jfo.2010.11.012. J Fr Ophtalmol. 2011. PMID: 21439677 Review. French.
-
Multiplex ligation-dependent probe amplification (MLPA) in tumor diagnostics and prognostics.Diagn Mol Pathol. 2012 Dec;21(4):189-206. doi: 10.1097/PDM.0b013e3182595516. Diagn Mol Pathol. 2012. PMID: 23111197 Review.
Cited by
-
Small Choroidal Melanoma: Correlation between Clinical Characteristics and Metastatic Potential.Ocul Oncol Pathol. 2021 Dec;7(6):437-446. doi: 10.1159/000519672. Epub 2021 Sep 16. Ocul Oncol Pathol. 2021. PMID: 35087820 Free PMC article.
-
Concurrence of chromosome 3 and 4 aberrations in human uveal melanoma.Oncol Rep. 2017 Apr;37(4):1927-1934. doi: 10.3892/or.2017.5496. Epub 2017 Mar 8. Oncol Rep. 2017. PMID: 28350068 Free PMC article.
-
Molecular pathology of uveal melanoma.Eye (Lond). 2013 Feb;27(2):230-42. doi: 10.1038/eye.2012.255. Epub 2012 Dec 7. Eye (Lond). 2013. PMID: 23222563 Free PMC article. Review.
-
Optimal Fixation Conditions and DNA Extraction Methods for MLPA Analysis on FFPE Tissue-Derived DNA.Am J Clin Pathol. 2017 Jan 1;147(1):60-68. doi: 10.1093/ajcp/aqw205. Am J Clin Pathol. 2017. PMID: 28122725 Free PMC article.
-
Small High-Risk Uveal Melanomas Have a Lower Mortality Rate.Cancers (Basel). 2021 May 8;13(9):2267. doi: 10.3390/cancers13092267. Cancers (Basel). 2021. PMID: 34066842 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical